Drug Trial Radar · NCT06880081
Study of PN20 in Adult Patients With Primary Immune Thrombocytopenia (ITP)
Last checked: Nov 19, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
12
Actual
Start
Mar 7, 2025
Primary completion
Feb 14, 2026
Study completion Feb 14, 2026
Sponsor
- Lead sponsor
- Chongqing Peg-Bio Biopharm Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Mar 17, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main aim of this clinical trial is to assess the safety and tolerability of PN20 in adult patients with primary immune thrombocytopenia (ITP). The main questions it aims to answer are: * Is PN20 safe in these patients? * Could these patients potentially benefit from PN20 treatment? Participants will * Receive one subcutaneous injection of PN20 according to weight; * Visit the clinic for assessment.
Conditions
- Primary Immune Thrombocytopenia (ITP)
Interventions
PN20 treatmentDrug
Three dose cohorts, single dose, subcutaneous injections
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse Event (AE)Time frame: Treatment and post-treatment follow-up period (28 days after a single dose)
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Affiliated Hospital of Guizhou Medical University
Guiyang, Guizhou, China
The Second Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, China
Jining First People's Hospital
Jining, Shandong, China
Hematology Hospital of Chinese Academy of Medical Sciences
Tianjin, Tianjin Municipality, China
The Second Affiliated Hospital of Kunming Medical University
Kunming, Yunnan, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.